Onepot AI is building an end-to-end platform that fuses advanced machine learning with highly automated laboratories to shorten chemical synthesis cycles from months to days. Its proprietary AI chemist, Phil, designs and optimizes reaction pathways while the company’s first physical lab, POT-1, executes and meticulously records every experimental variable. This closed-loop data capture produces reproducible, high-quality datasets that continuously improve the system’s predictive power, enabling the expansion of chemical space previously considered impractical. Biotech and pharmaceutical clients can order target compounds from Onepot’s catalog, after which the company synthesizes and ships the molecules. Founders Daniil Boiko and Andrei Tyrin claim their approach can at least double the pace of traditional drug discovery workflows. Fresh capital will fund a second laboratory in San Francisco, significantly increasing commercial capacity. Ultimately, Onepot AI aims to remove synthetic feasibility as a constraint on medicinal chemistry innovation.

Total raised

$13M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2025